Which has stronger earnings & valuation, INVA or LQDA?

Innoviva has higher earnings, but lower revenue than Liquidia. Innoviva is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.71 $271.17M $4.10 5.15 Liquidia $450.91M 14.03 -$68.92M $1.37 51.60

Is INVA or LQDA more profitable?

Innoviva has a net margin of 81.19% compared to Liquidia's net margin of 30.74%. Liquidia's return on equity of 149.65% beat Innoviva's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 81.19% 28.03% 20.19% Liquidia 30.74% 149.65% 36.30%

Does the media prefer INVA or LQDA?

In the previous week, Innoviva and Innoviva both had 8 articles in the media. Innoviva's average media sentiment score of 0.85 beat Liquidia's score of 0.73 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AMRX or INVA?

In the previous week, Innoviva had 4 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 8 mentions for Innoviva and 4 mentions for Amneal Pharmaceuticals. Innoviva's average media sentiment score of 0.85 beat Amneal Pharmaceuticals' score of 0.75 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innoviva 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INVA or DFTX?

In the previous week, Definium Therapeutics had 7 more articles in the media than Innoviva. MarketBeat recorded 15 mentions for Definium Therapeutics and 8 mentions for Innoviva. Innoviva's average media sentiment score of 0.85 beat Definium Therapeutics' score of 0.52 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is INVA or MANE more profitable?

Innoviva has a net margin of 81.19% compared to Veradermics' net margin of 0.00%. Innoviva's return on equity of 28.03% beat Veradermics' return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 81.19% 28.03% 20.19% Veradermics N/A N/A N/A

Does the media favor INVA or MANE?

In the previous week, Innoviva had 7 more articles in the media than Veradermics. MarketBeat recorded 8 mentions for Innoviva and 1 mentions for Veradermics. Innoviva's average media sentiment score of 0.85 beat Veradermics' score of 0.00 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, INVA or INDV?

Innoviva has higher earnings, but lower revenue than Indivior. Innoviva is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 3.71 $271.17M $4.10 5.15 Indivior $1.24B 3.49 $210M $2.79 13.11

Is INVA or INDV more profitable?

Innoviva has a net margin of 81.19% compared to Indivior's net margin of 26.65%. Innoviva's return on equity of 28.03% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Innoviva 81.19% 28.03% 20.19% Indivior 26.65% -283.11% 36.85%

Does the media refer more to INVA or INDV?

In the previous week, Innoviva had 5 more articles in the media than Indivior. MarketBeat recorded 8 mentions for Innoviva and 3 mentions for Indivior. Innoviva's average media sentiment score of 0.85 beat Indivior's score of 0.61 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Innoviva (INVA) Competitors

$21.11 -0.12 (-0.57%)

Closing price 04:00 PM Eastern

Extended Trading

$21.12 +0.00 (+0.02%)

As of 07:30 PM Eastern

Compare

INVA vs. LQDA, AMRX, DFTX, MANE, and INDV

Should you buy Innoviva stock or one of its competitors? Innoviva's main competitors and comparable companies include Liquidia (LQDA), Amneal Pharmaceuticals (AMRX), Definium Therapeutics (DFTX), Veradermics (MANE), and Indivior (INDV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Innoviva compare to Liquidia?

Innoviva (NASDAQ:INVA) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

99.1% of Innoviva shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Comparatively, 25.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Innoviva has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

In the previous week, Innoviva and Innoviva both had 8 articles in the media. Innoviva's average media sentiment score of 0.85 beat Liquidia's score of 0.73 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva presently has a consensus target price of $34.80, suggesting a potential upside of 64.85%. Liquidia has a consensus target price of $98.08, suggesting a potential upside of 38.75%. Given Innoviva's higher probable upside, research analysts clearly believe Innoviva is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Innoviva has a net margin of 81.19% compared to Liquidia's net margin of 30.74%. Liquidia's return on equity of 149.65% beat Innoviva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	81.19%	28.03%	20.19%
Liquidia	30.74%	149.65%	36.30%

Innoviva has higher earnings, but lower revenue than Liquidia. Innoviva is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.71	$271.17M	$4.10	5.15
Liquidia	$450.91M	14.03	-$68.92M	$1.37	51.60

Summary

Liquidia beats Innoviva on 10 of the 16 factors compared between the two stocks.

How does Innoviva compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Innoviva (NASDAQ:INVA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Innoviva has a net margin of 81.19% compared to Amneal Pharmaceuticals' net margin of 5.05%. Innoviva's return on equity of 28.03% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Innoviva	81.19%	28.03%	20.19%

Amneal Pharmaceuticals currently has a consensus price target of $21.00, indicating a potential upside of 3.96%. Innoviva has a consensus price target of $34.80, indicating a potential upside of 64.85%. Given Innoviva's higher probable upside, analysts clearly believe Innoviva is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Innoviva	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Innoviva had 4 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 8 mentions for Innoviva and 4 mentions for Amneal Pharmaceuticals. Innoviva's average media sentiment score of 0.85 beat Amneal Pharmaceuticals' score of 0.75 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.33, suggesting that its stock price is 67% less volatile than the broader market.

Innoviva has lower revenue, but higher earnings than Amneal Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	2.14	$72.06M	$0.49	41.22
Innoviva	$411.33M	3.71	$271.17M	$4.10	5.15

Summary

Innoviva beats Amneal Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Innoviva compare to Definium Therapeutics?

Innoviva (NASDAQ:INVA) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

99.1% of Innoviva shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Innoviva has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.71	$271.17M	$4.10	5.15
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Innoviva currently has a consensus target price of $34.80, indicating a potential upside of 64.85%. Definium Therapeutics has a consensus target price of $64.88, indicating a potential upside of 69.79%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Definium Therapeutics is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00

Innoviva has a net margin of 81.19% compared to Definium Therapeutics' net margin of 0.00%. Innoviva's return on equity of 28.03% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	81.19%	28.03%	20.19%
Definium Therapeutics	N/A	-84.01%	-63.66%

In the previous week, Definium Therapeutics had 7 more articles in the media than Innoviva. MarketBeat recorded 15 mentions for Definium Therapeutics and 8 mentions for Innoviva. Innoviva's average media sentiment score of 0.85 beat Definium Therapeutics' score of 0.52 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Innoviva has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

Summary

Innoviva beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Innoviva compare to Veradermics?

Innoviva (NASDAQ:INVA) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, Innoviva had 7 more articles in the media than Veradermics. MarketBeat recorded 8 mentions for Innoviva and 1 mentions for Veradermics. Innoviva's average media sentiment score of 0.85 beat Veradermics' score of 0.00 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Innoviva shares are held by institutional investors. 2.0% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Innoviva has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.71	$271.17M	$4.10	5.15
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

Innoviva presently has a consensus target price of $34.80, suggesting a potential upside of 64.85%. Veradermics has a consensus target price of $153.00, suggesting a potential upside of 30.22%. Given Innoviva's higher possible upside, analysts plainly believe Innoviva is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Innoviva has a net margin of 81.19% compared to Veradermics' net margin of 0.00%. Innoviva's return on equity of 28.03% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	81.19%	28.03%	20.19%
Veradermics	N/A	N/A	N/A

Summary

Innoviva beats Veradermics on 12 of the 14 factors compared between the two stocks.

How does Innoviva compare to Indivior?

Innoviva (NASDAQ:INVA) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Innoviva has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market. Comparatively, Indivior has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Innoviva has a net margin of 81.19% compared to Indivior's net margin of 26.65%. Innoviva's return on equity of 28.03% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	81.19%	28.03%	20.19%
Indivior	26.65%	-283.11%	36.85%

In the previous week, Innoviva had 5 more articles in the media than Indivior. MarketBeat recorded 8 mentions for Innoviva and 3 mentions for Indivior. Innoviva's average media sentiment score of 0.85 beat Indivior's score of 0.61 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Innoviva has higher earnings, but lower revenue than Indivior. Innoviva is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.71	$271.17M	$4.10	5.15
Indivior	$1.24B	3.49	$210M	$2.79	13.11

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Innoviva presently has a consensus price target of $34.80, suggesting a potential upside of 64.85%. Indivior has a consensus price target of $45.17, suggesting a potential upside of 23.44%. Given Innoviva's higher possible upside, analysts plainly believe Innoviva is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Indivior	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Innoviva beats Indivior on 10 of the 16 factors compared between the two stocks.

Get Innoviva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INVA vs. The Competition

Export

Metric	Innoviva	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.53B	$12.69B	$7.35B	$13.05B
Dividend Yield	N/A	2.62%	2.52%	14.18%
P/E Ratio	5.15	787.36	273.78	25.68
Price / Sales	3.71	750.76	606.30	77.83
Price / Cash	4.22	91.32	80.06	52.35
Price / Book	1.34	10.59	10.44	6.34
Net Income	$271.17M	$2.83B	$3.50B	$360.56M
7 Day Performance	0.62%	-2.63%	-3.03%	-2.83%
1 Month Performance	0.67%	-1.41%	-4.16%	-4.08%
1 Year Performance	10.93%	-0.33%	13.20%	3.85%

Innoviva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INVA Innoviva	2.9658 of 5 stars	$21.11 -0.6%	$34.80 +64.9%	+12.6%	$1.53B	$411.33M	5.15	159	Positive News
LQDA Liquidia	3.6097 of 5 stars	$66.88 -2.2%	$98.08 +46.7%	+237.9%	$5.99B	$158.32M	48.82	216	News Coverage High Trading Volume
AMRX Amneal Pharmaceuticals	2.9652 of 5 stars	$18.71 +2.4%	$20.14 +7.7%	+110.3%	$5.98B	$3.02B	38.18	8,500	High Trading Volume
DFTX Definium Therapeutics	2.8751 of 5 stars	$38.81 +0.3%	$64.88 +67.2%	+260.0%	$5.21B	N/A	N/A	40	Trending News Insider Trade
MANE Veradermics	1.9748 of 5 stars	$107.16 -1.4%	$153.00 +42.8%	N/A	$4.46B	N/A	N/A	21	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INVA) was last updated on 9/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innoviva (INVA) Competitors

INVA vs. LQDA, AMRX, DFTX, MANE, and INDV

How does Innoviva compare to Liquidia?

Summary

How does Innoviva compare to Amneal Pharmaceuticals?

Summary

How does Innoviva compare to Definium Therapeutics?

Summary

How does Innoviva compare to Veradermics?

Summary

How does Innoviva compare to Indivior?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innoviva (INVA) Competitors

INVA vs. LQDA, AMRX, DFTX, MANE, and INDV

How does Innoviva compare to Liquidia?

Do insiders and institutionals have more ownership in INVA or LQDA?

Which has more volatility & risk, INVA or LQDA?

Does the media prefer INVA or LQDA?

Do analysts prefer INVA or LQDA?

Is INVA or LQDA more profitable?

Which has stronger earnings & valuation, INVA or LQDA?

Summary

How does Innoviva compare to Amneal Pharmaceuticals?

Do institutionals and insiders believe in AMRX or INVA?

Is AMRX or INVA more profitable?

Do analysts prefer AMRX or INVA?

Does the media prefer AMRX or INVA?

Which has more volatility and risk, AMRX or INVA?

Which has better earnings & valuation, AMRX or INVA?

Summary

How does Innoviva compare to Definium Therapeutics?

Do insiders and institutionals hold more shares of INVA or DFTX?

Which has higher valuation and earnings, INVA or DFTX?

Do analysts recommend INVA or DFTX?

Is INVA or DFTX more profitable?

Does the media prefer INVA or DFTX?

Which has more volatility and risk, INVA or DFTX?

Summary

How does Innoviva compare to Veradermics?

Does the media favor INVA or MANE?

Do insiders & institutionals hold more shares of INVA or MANE?

Which has higher earnings and valuation, INVA or MANE?

Do analysts prefer INVA or MANE?

Is INVA or MANE more profitable?

Summary

How does Innoviva compare to Indivior?

Which has more risk and volatility, INVA or INDV?

Is INVA or INDV more profitable?

Does the media refer more to INVA or INDV?

Which has higher earnings & valuation, INVA or INDV?

Do insiders and institutionals hold more shares of INVA or INDV?

Do analysts recommend INVA or INDV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA vs. The Competition

Innoviva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools